S&P 500   3,368.01 (+0.22%)
DOW   28,001.33 (+0.76%)
QQQ   268.43 (-0.70%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,368.01 (+0.22%)
DOW   28,001.33 (+0.76%)
QQQ   268.43 (-0.70%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,368.01 (+0.22%)
DOW   28,001.33 (+0.76%)
QQQ   268.43 (-0.70%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,368.01 (+0.22%)
DOW   28,001.33 (+0.76%)
QQQ   268.43 (-0.70%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
Log in

NASDAQ:REPHRecro Pharma Stock Price, Forecast & News

$3.36
+0.02 (+0.60 %)
(As of 08/11/2020 02:51 PM ET)
Add
Compare
Today's Range
$3.36
Now: $3.36
$3.54
50-Day Range
$4.06
MA: $4.40
$4.93
52-Week Range
$3.13
Now: $3.36
$19.21
Volume5,932 shs
Average Volume248,775 shs
Market Capitalization$79.20 million
P/E Ratio16.80
Dividend YieldN/A
Beta0.75
Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. The company also develops early-stage product candidates, which include Dex-IN, an intranasal formulation of dexmedetomidine for use in clinical sedation; and two novel neuromuscular blocking agents and a related proprietary chemical reversal agent. In addition, it provides formulation and development services to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for commercial partners. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Read More
Recro Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.44 per share
Book Value($0.30) per share

Profitability

Net Income$-18,630,000.00

Miscellaneous

Employees255
Market Cap$79.20 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$3.36
+0.02 (+0.60 %)
(As of 08/11/2020 02:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

How has Recro Pharma's stock been impacted by COVID-19 (Coronavirus)?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPH shares have decreased by 63.4% and is now trading at $3.36.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Recro Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Recro Pharma
.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Recro Pharma
.

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings data on Monday, August, 10th. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.09. Recro Pharma had a negative return on equity of 15.25% and a negative net margin of 25.38%.
View Recro Pharma's earnings history
.

What price target have analysts set for REPH?

2 equities research analysts have issued 12-month target prices for Recro Pharma's shares. Their forecasts range from $12.00 to $18.00. On average, they anticipate Recro Pharma's share price to reach $15.00 in the next year. This suggests a possible upside of 346.4% from the stock's current price.
View analysts' price targets for Recro Pharma
.

Has Recro Pharma been receiving favorable news coverage?

News headlines about REPH stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Recro Pharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Recro Pharma
.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,240,000 shares, an increase of 39.7% from the January 31st total of 887,600 shares. Based on an average trading volume of 309,400 shares, the short-interest ratio is currently 4.0 days. Approximately 6.5% of the company's shares are short sold.
View Recro Pharma's Short Interest
.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.84%), GW&K Investment Management LLC (1.43%), Russell Investments Group Ltd. (0.77%), Cadence Capital Management LLC (0.71%), Strs Ohio (0.41%) and Aigen Investment Management LP (0.31%). Company insiders that own Recro Pharma stock include Arnaud Ajdler and Geraldine Henwood.
View institutional ownership trends for Recro Pharma
.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., and UBS Group AG.
View insider buying and selling activity for Recro Pharma
.

Which institutional investors are buying Recro Pharma stock?

REPH stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Russell Investments Group Ltd., Strs Ohio, Cadence Capital Management LLC, Trexquant Investment LP, Aigen Investment Management LP, GW&K Investment Management LLC, and Diversified Trust Co.
View insider buying and selling activity for Recro Pharma
.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $3.36.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $79.20 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Recro Pharma employs 255 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.